Related Experiment Videos
[Systemic chemotherapy in advanced bladder cancer. New aspects].
Wiener Klinische Wochenschrift
|January 23, 1987
Summary
Systemic chemotherapy, including cisplatin and methotrexate, offers over 20% remission rates for advanced bladder cancer. This approach can prolong tumor-free survival and is effective for locally-advanced disease, sometimes combined with radiation.
Area of Science:
- Oncology
- Urologic Oncology
- Cancer Therapeutics
Context:
- Advanced bladder cancer treatment landscape.
- Growing role of systemic chemotherapy.
- Limited options for metastatic and locally-advanced disease.
Purpose:
- To review the efficacy of systemic chemotherapy in advanced bladder cancer.
- To highlight chemotherapy regimens and their outcomes.
- To discuss chemotherapy's role in locally-advanced disease.
Summary:
- Cisplatin- and methotrexate-based chemotherapy yields >20% complete remission in metastatic bladder cancer, enabling prolonged tumor-free survival.
- Systemic chemotherapy is indicated for locally-advanced bladder cancer, alone or with radiotherapy.
- Integrated radiotherapy and chemotherapy can eradicate T3 tumors in over 70% of cases.
Impact:
- Demonstrates the significant impact of systemic chemotherapy on advanced bladder cancer outcomes.
- Provides evidence for improved survival and tumor control.
- Identifies areas for further research, such as the effect on micrometastases.